Pfizer's Viagra losing market share in Russia

The share of US pharma giant Pfizer’s (NYSE: PFE) erectile dysfunction drug Viagra (sildenafil) in the Russian market is steadily declining, due to the ever-growing competition from local generics and serious interruptions with supplies of the drug from Europe.

According to the Russian pharma analytics agency, the DSM Group, over the past 40 weeks, retail sales of the drug – once of the most popular in Russia - have declined by 5% in value terms and by 22% in volume year-on-year basis.

As representatives of SoyuzPharma, the Russian Association of Pharmacies, said in an interview with the Russian Expert business paper, the supplies of Viagra to Russia did not stop completely, but have significantly declined.